Proteostasis raises $45mm through Series A round
Proteostasis Therapeutics (treatments for genetic and degenerative diseases) brought in $45mm through its Series A round. Seed investor HealthCare Ventures returned, and was joined by new participants Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund, and Genzyme Ventures.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com